Marksans Pharma, is a pharmaceutical formulation manufacturer on Wednesday reported a rise of 26.8% in its consolidated net profit to Rs 626 million for the quarter ended June 2021 (Q1FY22) from Rs 494 million in the same period a year ago. The company's PAT margin increased to 17.6% in Q1FY22 versus 14.9% in Q1FY21.

Consolidated operating revenue increased by 5.4% to Rs 3,490 million in the quarter under review, from Rs 3,312 million in the corresponding quarter last year.

EBITDA came at Rs 773 million in Q1FY22 as compared to Rs 700 million in Q1 FY21, an increase of 10.5% yoy. EBITDA Margin stood at 22.2% as against 21.1% in Q1 FY21, Margin expansion of 110 basis points.

Mark Saldanha, Managing Director of the Company said, "We recorded a sales growth of 5.4% led by increased penetration in regulated markets despite pandemic induced logistics issues. We drove gains from operating efficiencies and a debt free balance sheet resulting in our bottom line increasing by 26.8% in Q1FY22 on a year-on-year basis."

Saldanha added, "We are delighted to have OrbiMed as a financial partner in our mission to become a global pharmaceutical company. We will continue to invest in our businesses, with Orbimed’s global network and resources enabling us to accelerate our growth momentum in the long term."

Shares of the company declined Rs 4.20, or 5.49%, to trade  at  Rs 72.30.  The total volume of shares traded  was 1,126,560 at  the BSE (3.29 p.m, Wednesday).